Oncological Surgery in Times of COVID-19: Effectiveness of Preoperative Screening for Sars-Cov-2
To evaluate the incidence of patients with a positive test for SARS-CoV-2, performed in the preoperative screening for patients treated at the institution
SARS-CoV-2|Oncology|Surgery
DIAGNOSTIC_TEST: PT-PCR test for SARS-CoV-2
Incidence of patients with a positive test for SARS-CoV-2, detected in the preoperative screening program, Describe the incidence of patients with a positive test for SARS-CoV-2, detected in the preoperative screening program in our center, May- December 2020
Incidence of SARS-CoV-2 infection in the postoperative period in patients with negative screening test;, Describe the incidence of SARS-CoV-2 infection in the postoperative period in patients with negative screening test., Up to 30 days|Postoperative complications, Postoperative complications will be recorded, according to the Clavien-Dindo classification., Up to 30 days|Mortality, To evaluate the risk of all-cause mortality, 30 days|Delay in the cancer treatment, Assess the impact of delayed cancer treatment, May 2020- March 2021
Cohort, prospective, observational study to evaluate the incidence of asymptomatic patients with a positive SARS-CoV-2 test detected in the preoperative screening program of the institution.